NCT04528004View on ClinicalTrials.gov

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 26, 2020

Primary Completion Date

November 30, 2024

Study Completion Date

July 31, 2025

Conditions
Heart Failure, SystolicHeart Failure NYHA Class IVMetabolic Disturbance
Interventions
DRUG

Nicotinamide riboside

Nicotinamide riboside 250mg capsules

OTHER

Placebo

Matching placebo 250mg capsules

Trial Locations (1)

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Washington

OTHER